VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease
AbstractInterstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease. View Full-Text
Share & Cite This Article
Barratt, S.L.; Flower, V.A.; Pauling, J.D.; Millar, A.B. VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. Int. J. Mol. Sci. 2018, 19, 1269.
Barratt SL, Flower VA, Pauling JD, Millar AB. VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. International Journal of Molecular Sciences. 2018; 19(5):1269.Chicago/Turabian Style
Barratt, Shaney L.; Flower, Victoria A.; Pauling, John D.; Millar, Ann B. 2018. "VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease." Int. J. Mol. Sci. 19, no. 5: 1269.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.